PEOPLE - World Heart announces some management changes:
This article was originally published in Clinica
Ontario, Canada-based pulsatile ventricular assist device provider World Heart has announced some management changes. Jal Jassawalla has been named president and CEO, effective immediately. Mr Jassawalla succeeds Roderick Bryden, who recently resigned. Piet Jansen has been appointed managing director of the firm's European business. Dr Jansen will also continue in his role as chief medical officer. John Marinchak has been named vice-president of marketing and sales. He joined World Heart in November 2003. Finally, Robert Corson, who joined the company in November 1997, has been promoted to vice-president of manufacturing, and will be based in the firm's Oakland facilities.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.